Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.76)
# 629
Out of 4,835 analysts
414
Total ratings
46.8%
Success rate
19.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCGN Ocugen | Reiterated: Buy | $11 | $1.02 | +978.43% | 7 | Sep 10, 2026 | |
| BEAM Beam Therapeutics | Reiterated: Buy | $78 | $23.99 | +225.14% | 7 | Sep 9, 2026 | |
| BLTE Belite Bio | Initiated Coverage: Buy | $303 | $177.28 | +70.92% | 1 | Sep 4, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Buy | $83 → $37 | $14.30 | +158.74% | 26 | Sep 3, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $114 | $65.68 | +73.57% | 23 | Aug 31, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $429 | $248.68 | +72.51% | 37 | Aug 28, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $20 | $14.73 | +35.78% | 30 | Aug 20, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $104 → $106 | $72.44 | +46.33% | 2 | Aug 12, 2026 | |
| GUTS Fractyl Health | Reiterated: Buy | $8 | $0.64 | +1,150.00% | 18 | Aug 12, 2026 | |
| NGNE Neurogene | Reiterated: Buy | $180 → $166 | $35.48 | +367.87% | 6 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.35 | +198.51% | 23 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $5.02 | +238.65% | 26 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 | $11.74 | +317.38% | 23 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.64 | +681.25% | 25 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $227 → $232 | $150.13 | +54.53% | 22 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $151 → $154 | $104.00 | +48.08% | 31 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $436 → $442 | $515.44 | -14.25% | 39 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 → $38 | $11.21 | +238.98% | 4 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $43 | $4.59 | +836.82% | 15 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $5.00 | +360.00% | 15 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $83 → $114 | $347.00 | n/a | 5 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $20.45 | n/a | 2 | Sep 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $143.72 | n/a | 4 | Jan 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $121.47 | n/a | 1 | Jan 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $44.51 | n/a | 4 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 → $27 | $98.22 | n/a | 2 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 | $0.1485 | n/a | 5 | Nov 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $51.72 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $2.70 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $29.05 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $16 | $1.61 | n/a | 5 | May 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.51 | n/a | 2 | Jan 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.75 | n/a | 1 | May 13, 2014 |
Ocugen
Sep 10, 2026
Reiterated: Buy
Price Target: $11
Current: $1.02
Upside: +978.43%
Beam Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $78
Current: $23.99
Upside: +225.14%
Belite Bio
Sep 4, 2026
Initiated Coverage: Buy
Price Target: $303
Current: $177.28
Upside: +70.92%
Ultragenyx Pharmaceutical
Sep 3, 2026
Reiterated: Buy
Price Target: $83 → $37
Current: $14.30
Upside: +158.74%
BioMarin Pharmaceutical
Aug 31, 2026
Reiterated: Buy
Price Target: $114
Current: $65.68
Upside: +73.57%
Alnylam Pharmaceuticals
Aug 28, 2026
Reiterated: Buy
Price Target: $429
Current: $248.68
Upside: +72.51%
Arcturus Therapeutics Holdings
Aug 20, 2026
Reiterated: Buy
Price Target: $20
Current: $14.73
Upside: +35.78%
BridgeBio Pharma
Aug 12, 2026
Reiterated: Buy
Price Target: $104 → $106
Current: $72.44
Upside: +46.33%
Fractyl Health
Aug 12, 2026
Reiterated: Buy
Price Target: $8
Current: $0.64
Upside: +1,150.00%
Neurogene
Aug 12, 2026
Reiterated: Buy
Price Target: $180 → $166
Current: $35.48
Upside: +367.87%
Aug 12, 2026
Reiterated: Buy
Price Target: $10
Current: $3.35
Upside: +198.51%
Aug 11, 2026
Reiterated: Buy
Price Target: $17
Current: $5.02
Upside: +238.65%
Aug 6, 2026
Reiterated: Buy
Price Target: $49
Current: $11.74
Upside: +317.38%
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $0.64
Upside: +681.25%
Aug 5, 2026
Reiterated: Buy
Price Target: $227 → $232
Current: $150.13
Upside: +54.53%
Aug 5, 2026
Reiterated: Buy
Price Target: $151 → $154
Current: $104.00
Upside: +48.08%
Aug 4, 2026
Reiterated: Hold
Price Target: $436 → $442
Current: $515.44
Upside: -14.25%
Aug 3, 2026
Reiterated: Buy
Price Target: $37 → $38
Current: $11.21
Upside: +238.98%
May 19, 2026
Reiterated: Buy
Price Target: $43
Current: $4.59
Upside: +836.82%
Apr 21, 2026
Reiterated: Buy
Price Target: $23
Current: $5.00
Upside: +360.00%
Feb 28, 2022
Reiterated: Buy
Price Target: $83 → $114
Current: $347.00
Upside: n/a
Sep 15, 2021
Upgraded: Buy
Price Target: n/a
Current: $20.45
Upside: n/a
Jan 4, 2021
Upgraded: Buy
Price Target: n/a
Current: $143.72
Upside: n/a
Jan 4, 2021
Upgraded: Buy
Price Target: n/a
Current: $121.47
Upside: n/a
Jun 25, 2020
Reiterated: Hold
Price Target: n/a
Current: $44.51
Upside: n/a
Dec 16, 2019
Reiterated: Buy
Price Target: $18 → $27
Current: $98.22
Upside: n/a
Nov 9, 2018
Downgraded: Hold
Price Target: $18
Current: $0.1485
Upside: n/a
Oct 9, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $51.72
Upside: n/a
Oct 9, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $2.70
Upside: n/a
Oct 9, 2018
Initiated Coverage: Buy
Price Target: $35
Current: $29.05
Upside: n/a
May 4, 2017
Reiterated: Buy
Price Target: $19 → $16
Current: $1.61
Upside: n/a
Jan 11, 2017
Reiterated: Hold
Price Target: n/a
Current: $1.51
Upside: n/a
May 13, 2014
Reiterated: Hold
Price Target: n/a
Current: $3.75
Upside: n/a